Bio Medica Laboratories IPO Listing Today 29 May 2026: Opens at Rs 105 – Rs 34 Below Issue Price Rs 139 on NSE SME

Bio Medica Laboratories IPO listing today (29 May 2026): opened at Rs 105 on NSE SME – Rs 34 or 24.5% below issue price Rs 139. GMP was Rs 0. Indore parenteral CDMO. OFS component 3,77,000 shares added selling pressure.

The Bio Medica Laboratories IPO listing today (29 May 2026) opened at Rs 105 on NSE SME – a significant discount of Rs 34 or 24.5 percent below the issue price of Rs 139. The Bio Medica Laboratories IPO listing is today’s weakest debut among the three IPOs listing on NSE SME and BSE SME. The nil grey market premium (GMP Rs 0) throughout the subscription period had signalled a listing near or below issue price – but the actual 24.5 percent discount is steeper than a flat-GMP scenario typically implies. The OFS component of 3,77,000 shares (existing shareholders exiting) added supply at listing and likely contributed to the sharp opening discount.

Bio Medica Laboratories IPO Listing: Key Numbers

• Listing Price: Rs 105 on NSE SME (29 May 2026)
• Issue Price: Rs 139 per share (upper band of Rs 132-139)
• Listing Loss: Rs 34 per share (-24.5% below issue price)
• GMP (pre-listing): Rs 0 – weak debut was expected, but 24.5% discount is sharper than typical nil-GMP scenarios
• Issue Size: Rs 52.43 crore (Fresh Rs 47.19 crore + OFS Rs 5.24 crore – 3,77,000 shares)
• OFS impact: 3,77,000 shares sold by existing shareholders – exiting at listing creates immediate supply
• Minimum allotment value at listing: 800 shares × Rs 105 = Rs 84,000 (applied at Rs 1,11,200 upper band – loss Rs 27,200 per lot)

Track Bio Medica Laboratories live price on the .

Why the Bio Medica Laboratories IPO Listing Opened 24.5% Below Issue Price

1. OFS Component Created Immediate Selling Pressure

The OFS component of 3,77,000 shares in the Bio Medica Laboratories IPO means that existing shareholders who sold at Rs 139 (issue price) during the IPO have already locked in their exit price. However, at listing, these shares – now in the hands of allottees – face the same allottees potentially selling alongside OFS-related market dynamics. When a small NSE SME stock has both retail profit-booking and OFS-related supply at listing, the opening price can gap significantly below issue price.

2. No Institutional Anchor Support

Unlike Q-Line Biotech (which had Vikas Khemani as pre-IPO anchor at Rs 343 – providing a clear institutional validation), Bio Medica Laboratories had no disclosed institutional anchor. In the absence of a strong institutional buy-side presence, the listing price discovery at NSE SME is entirely retail-driven – and retail sentiment on a nil-GMP stock tends to produce weak openings as sellers outnumber buyers.

3. The Rs 139 Issue Price Was Aggressively Valued

Bio Medica Laboratories is an Indore-based parenteral pharmaceutical CDMO with FY-level revenue that, at Rs 139 per share, was priced at a multiple that the secondary market has re-rated on Day 1. At Rs 105, the market is effectively placing a lower earnings multiple on the business than the Rs 139 IPO price implied. This is a common occurrence in SME IPOs where the issue price is set at the upper band of the pricing range – the market sometimes finds a lower equilibrium in the first few sessions.

Tap to Access Best Research Pieces on Univest

About Bio Medica Laboratories: Parenteral CDMO With Strong Sector Tailwinds

Bio Medica Laboratories Limited, incorporated in 2015 in Indore, Madhya Pradesh, is a B2B pharmaceutical contract development and manufacturing organisation (CDMO) specialising in parenteral formulations – liquid injectables (Large Volume Parenterals and Small Volume Parenterals) and dry powder injectables for human healthcare and veterinary segments. GMP-certified by the Madhya Pradesh FDA and GLP-certified. Supplies branded pharma companies in 11-plus Indian states.

• Business: Parenteral CDMO – LVP/SVP liquid injectables, dry powder injectables, veterinary pharma
• Certifications: GMP (MP FDA) and GLP certified
• IPO use: Rs 28.50 crore for new manufacturing unit + Rs 6.50 crore debt repayment

Bio Medica Laboratories Allottees: What to Do Now

With the Bio Medica Laboratories IPO listing at Rs 105 – Rs 34 below issue price Rs 139 – allottees face a significant Day 1 loss. The decision to hold or exit depends on fundamental conviction in the parenteral CDMO business model and the specific company’s ability to grow revenue and PAT through FY26 and FY27. The CDMO sector has strong structural tailwinds (outsourcing growth, China+1 shift, CDSCO regulatory framework) but individual CDMO companies must demonstrate consistent order wins and capacity utilisation to command valuation re-rating.

For allottees who applied for listing gain: the opportunity is not available at Rs 105 – the listing has gone against the position. Exiting at Rs 105 to prevent further downside is a valid choice if the holding is purely speculative. For investors with 12 to 18 month fundamental conviction: the new manufacturing unit (Rs 28.50 crore from IPO proceeds) is expected to add capacity in FY27 – if revenue and PAT visibility improves, a re-rating toward Rs 120 to Rs 130 over 6 to 12 months is possible, but carries execution risk. Consult a SEBI-registered advisor before any post-listing decision.

Track Bio Medica Laboratories live listing price on Univest

FAQs on Bio Medica Laboratories IPO Listing

What is Bio Medica Laboratories IPO listing price today?

Ans. Bio Medica Laboratories IPO listing price today (29 May 2026) is Rs 105 on NSE SME – a loss of Rs 34 or 24.5% below the issue price of Rs 139 (upper band). GMP was Rs 0. The OFS component (3,77,000 shares) added selling pressure at listing. Minimum lot allottees (800 shares at Rs 1,11,200) have a notional loss of approximately Rs 27,200 at listing.

Why did Bio Medica Laboratories IPO list below issue price?

Ans. Bio Medica Laboratories listed 24.5% below issue price for three reasons: (1) OFS component added selling supply at listing; (2) No institutional anchor – retail-only price discovery; (3) Rs 139 issue price was valued at a premium the secondary market re-rated on Day 1. GMP was Rs 0 – weak listing was indicated but the 24.5% discount is steeper than typical nil-GMP scenarios.

Also Read

Also Read: Q-Line Biotech IPO Listing Today: Lists at Rs 445, +29.7% on NSE SME

Also Read: Autofurnish IPO Listing Today: Lists at Rs 40 on BSE SME

Also Read: SMR Jewels IPO Closing Today: Last Day 29 May, GMP Rs 0

Also Read: Rajnandini Fashion India IPO Closing Today: GMP Rs 8

Disclaimer: This article is for informational and educational purposes only. Nothing in this article constitutes investment advice, a recommendation to buy or sell securities, or a solicitation of any offer to buy or sell securities. Univest is a SEBI-registered research analyst (INH000014019). Readers should conduct their own research and consult a SEBI-registered investment advisor before making any investment decisions. Past performance of any stock or sector is not indicative of future results. Investments in equity markets are subject to market risks.